Sugi Predict

Sugi Predict / Compounds / SCHEMBL462294

SCHEMBL462294

SCHEMBL462294

O=C(O)CC1CCC(c2ccc(O)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 12/20 0.62
▸ ESR1 P03372 6/20 0.62
▸ CYP3A4 P08684 2/20 0.62
▸ CYP2C9 P11712 2/20 0.62
▸ CYP2D6 P10635 1/20 0.56
▸ DGAT1 O75907 8/20 0.53
▸ FAAH O00519 1/20 0.50
▸ CHRM2 P08172 1/20 0.50
▸ SOAT1 P35610 1/20 0.50
▸ DGAT2 Q96PD7 1/20 0.50
▸ PDE10A Q9Y233 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18763873 1.00 ESR2 (0.62) ESR2ESR1CYP3A4CYP2C9CYP2D6
SCHEMBL2259544 1.00 ESR2 (0.62) ESR2ESR1CYP3A4CYP2C9CYP2D6
SCHEMBL4940938 0.95 DGAT1 (0.59) ESR2ESR1CYP3A4CYP2C9CYP2D6
SCHEMBL3538810 0.85 IDO1 (0.57) DGAT1FAAHCHRM2SOAT1DGAT2
SCHEMBL17318281 0.85 IDO1 (0.57) DGAT1FAAHCHRM2SOAT1DGAT2
SCHEMBL3538808 0.85 IDO1 (0.57) DGAT1FAAHCHRM2SOAT1DGAT2
SCHEMBL3537768 0.84 DGAT1 (0.56) DGAT1FAAHCHRM2SOAT1DGAT2
SCHEMBL3537767 0.84 DGAT1 (0.56) DGAT1FAAHCHRM2SOAT1DGAT2
SCHEMBL11108167 0.84 DGAT1 (0.55) CYP2C9DGAT1FAAHCHRM2SOAT1
SCHEMBL11108164 0.84 DGAT1 (0.55) CYP2C9DGAT1FAAHCHRM2SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10987322-B2 Immunoregulatory agents FLEXUS BIOSCIENCES, INC. (US) 2021-04-27 — — US disclosed
CN-106999450-A immunomodulator 弗莱塞斯生物科学公司 2017-08-01 — — CN disclosed
US-20170112785-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. 2017-04-27 — — US disclosed
EP-3151820-A1 IMMUNOREGULATORY AGENTS Flexus Biosciences, Inc. (US) 2017-04-12 — — EP disclosed
CN-106535884-A Immunoregulatory agents 弗雷克萨斯生物科学公司 2017-03-22 — — CN disclosed
WO-2015188085-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. (US) 2015-12-10 — — WO disclosed
EP-2234978-B1 CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 ASTRAZENECA AB (SE) 2015-02-25 — — EP disclosed
EP-2595970-B1 DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS SANOFI SA (FR) 2015-01-07 — — EP disclosed
EP-2391611-B1 THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-04-30 — — EP disclosed
US-8586594-B2 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBVIE INC. (US) 2013-11-19 — — US disclosed
US-8202878-B2 Type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease;Trans [4-(4-{3-[2-(1-adamantyl)-2-hydroxyethoxy]-1H-pyrazol-5-yl}phenyl)cyclohexyl]acetic acid ABBOTT LABORATORIES (US) 2012-06-19 — — US disclosed
WO-2012011081-A1 DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS SANOFI (FR) 2012-01-26 — — WO disclosed
EP-2391611-A1 THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-12-07 — — EP disclosed
US-7994179-B2 Carbamoyl compounds as DGAT1 inhibitors 190 ASTRAZENECA AB (SE) 2011-08-09 — — US disclosed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 — — US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 — — US disclosed
WO-2010086551-A1 THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-08-05 — — WO disclosed
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2009-12-03 — — US disclosed
US-20080182861-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBVIE INC. 2008-07-31 — — US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 ESR2 2111/4885ESR1 2469/4885CYP3A4 551/4885
US-20080182861-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME DGAT1, DGAT2, LCAT ESR2 4247/4885ESR1 4092/4885CYP3A4 1728/4885
US-20170112785-A1 IMMUNOREGULATORY AGENTS IDO1, IDO2, INMT ESR2 1493/4885ESR1 3892/4885CYP3A4 1482/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 ESR2 2062/4885ESR1 2414/4885CYP3A4 544/4885
US-10987322-B2 Immunoregulatory agents IDO1, IDO2, INMT ESR2 1493/4885ESR1 3892/4885CYP3A4 1482/4885
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 DGAT1, DGAT2, SOAT1 ESR2 3055/4885ESR1 4117/4885CYP3A4 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.